Related Experiment Video
Updated: Feb 25, 2026

Author Spotlight: Unlocking the Mysteries of Oral Potential Malignancies
Published on: August 11, 2023
OSFCOS: A core outcome set for clinical trials on oral submucous fibrosis management
Shailesh M Gondivkar1, Amol R Gadbail2, Monal Yuwanati3
1Department of Oral Medicine & Radiology, Government Dental College & Hospital, Nagpur, Maharashtra, India.
Background:
Oral Submucous Fibrosis (OSF) significantly impacts oral function, quality of life and poses challenges for effective treatment evaluation due to heterogeneity in outcome reporting across clinical trials. To date, no core outcome set (COS) exists for OSF trials, leading to significant heterogeneity in outcome reporting and difficulty in comparing interventions. This study aimed to develop a COS for OSF (OSFCOS) to standardize outcome reporting in clinical trials evaluating OSF management.
Methods:
The study followed COMET and COS-STAD guidelines and involved four stages: a systematic review of randomized controlled trials to identify reported outcomes; qualitative research using interviews and focus groups with OSF patients to capture patient-prioritized outcomes; a two-round Delphi survey with key stakeholders (patients, clinicians, researchers); and a consensus meeting to finalize core outcomes. Outcomes were rated using a 9-point GRADE scale, and consensus was predefined using standard thresholds.
Results:
A total of 20 outcomes were identified from systematic review and 31 from qualitative analysis. After triangulation & refinement, 16 unique outcomes were prioritized in Delphi Round 1 (n = 45). Delphi Round 2 (n = 25) rated 23 outcomes; 10 reached "consensus in." A consensus meeting with 17 stakeholders reviewed 13 outcomes and finalized 7 core outcomes for OSFCOS.
Conclusion:
This is the first COS developed specifically for OSF that offers a robust, stakeholder-driven framework for standardized outcome reporting, comparability and enhancing data synthesis in OSF trials for better evidence generation and patient care.
More Related Videos
05:57ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection
Published on: February 10, 2017
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Cystic Fibrosis: Management
Sinus disease and chronic...
Drugs for Treatment of Ulcerative Colitis in IBD